Azacitidine
Also known as: Azacytidine
Brand names: ONUREG VIDAZA
Therapeutic Indications
Azacitidine is indicated for:
Myelodysplastic syndromes, chronic myelomonocytic leukaemia, acute myeloid leukaemia
Irrespective of gender only Adults (18 years old or older)
Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:
- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder,
- acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
- AML with >30% marrow blasts according to the WHO classification.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Subcutaneous - 75 mg/m² once daily
Contraindications
Active ingredient Azacitidine is contraindicated in the following cases:
Lactation
No gender/age discrimination
It is unknown whether azacitidine/metabolites are excreted in human milk.
Due to the potential serious adverse reactions in the nursing child, breast-feeding is contraindicated during azacitidine therapy.
Advanced malignant hepatic tumours
No gender/age discrimination